DGX · Quest Diagnostics Inc
$242.76
-1.85 (-0.76%)
At close · Aug 28
Market Cap
$26.94B
Shares
110.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$242.76
Open$245.17
Day$242.27–245.28
52W close$173.49–245.00
Avg vol 30d993K
Short int3.3M · 3.0% float · 4.7d
Short vol64%
Last earningsJul 23, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 23
Up next
Next earnings call
Oct 23, 2026
Est · unconfirmed
· in 8 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 23, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very Low
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
+9%
above
RSI (14)
67
neutral
MACD trend
Negative
52-week position
97%
near high
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+20%
trailing
YTD return
+40%
this year
Relative strength
+7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $224 › 200d $200 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +119 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.01% of float · ▼ -9.8% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,100 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
33%
expanding
EPS growth
+14%
Y/Y
Free cash flow
$1.4B
Valuation
P/E 25.9
below peers
Buyback
$1.3B
remaining
Balance sheet
$5.3B
net debt
Quant / Vol
risk profile
Volatility
24%
annualized · 1-yr
Max drawdown
−12%
past year
ATR
2.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 23, 2026
Net revenues
· full year 2026
Initiated
$11.95B – $12.05B
prior FY $11.04B
midpoint +8.7% Y/Y
Adjusted diluted EPS
· full year 2026
Non-GAAP
Raised
$11.05 – $11.25
Apr 21, 2026
$10.63 – $10.83
changed to
Jul 23, 2026
$11.05 – $11.25
Prior guidance
period ended
· from the 8-K filed Oct 21, 2025
Reported diluted EPS
· Full year 2025
$8.58 – $8.66
Adjusted diluted EPS
· Full year 2025
$9.76 – $9.84
Guided vs delivered
· last 7 settled
Reported diluted EPS
Full year 2025
guided $8.58 – $8.66
$8.75
Beat +1.5%
Revenues
full-year 2024
guided $9.35B – $9.45B
$9.87B
Beat +5.0%
Reported EPS
full-year 2024
guided $7.69 – $7.99
$7.69
In line
Revenues
full-year 2023
guided $9.19B – $9.24B
$9.25B
Beat +0.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
67
Neutral
MACD trend
Negative
Bearish
52-week position
97%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $224 › 200d $200 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +119 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.01% of float · ▼ -9.8% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
1,100 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $173
Now $243 · 97%
Range high $245
vs 200-day avg +22%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Organic requisition volume | 13% | Q2 2026 | — |
|
|
|||
| Requisition volume | 13.1% | Q2 2026 | — |
|
|
|||
| Adjusted diluted EPS non-GAAP | $2.5 | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Diluted EPS (As reported) $2.24
+$0.04 Restructuring and integration charges
+$0.03 Other charges
+$0.05 Gains and losses on investments
+$0.25 Amortization expense
-$0.11 ETB
= Adjusted Diluted EPS $2.5
|
|||
| Adjusted operating income non-GAAP | $447M | Three Months Ended March 31, 2026 | — |
|
|
|||
| Adjusted operating income as a percentage of net revenues non-GAAP | 15.4% | Three Months Ended March 31, 2026 | — |
|
|
|||
| Adjusted Net income attributable to Quest Diagnostics non-GAAP | $1.12B | Full Year 2025 | — |
GAAP → non-GAAP reconciliationGAAP Net income attributable to Quest Diagnostics $992M
+$45M Restructuring and integration charges (a)
-$10M Change in fair value of contingent consideration (b)
+$39M Other charges (c)
-$4M Gains and losses on investments (d)
-$41M Other gains (e)
+$115M Amortization expense
-$18M ETB
= Adjusted Net income attributable to Quest Diagnostics $1.12B
|
|||
| Share repurchase cost | $452M | Twelve Months Ended December 31, 2025 | — |
| Share repurchases | 2.5M | Twelve Months Ended December 31, 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DGX
this stock
Quest Diagnostics Inc
|
$26.94B | +39.9% | +11.8% | 25.9 | 3.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$230.05B | +7.4% | +14.5% | 33.5 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.51B | -5.6% | +8.5% | 38.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$48.82B | +42.4% | -2.8% | — | 3.0% |
|
IQV
Iqvia Holdings Inc.
|
$43.79B | +16.1% | +41.6% | 32.6 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DGX | -0.7% | +4.2% | +20.4% | +4.2% | +39.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -1.1% | +1.2% | +7.0% | +1.2% | +27.1% |
Capital returns
Latest dividend
$0.86
/ share · ex Jul 8, 2026
Declared · upcoming
$0.86
/ share · ex Oct 6, 2026
Paid (TTM)
$3.32
/ share · 4 payouts
Dividend yield (TTM, derived)
1.37%
Buyback program
· as of Jun 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$1.30B
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1022079
CUSIP
74834L100
13F (30d)
753 filings
728 filers
Visit website
Investor relations